How should finerenone be added to guideline‑directed therapy in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction ≤40%) who have type 2 diabetes mellitus (T2DM) and chronic kidney disease (estimated glomerular filtration rate ≥25 mL/min/1.73 m², serum potassium ≤4.8 mmol/L)?

Finerenone in Heart Failure with Reduced Ejection Fraction

Add finerenone to guideline-directed therapy in patients with HFrEF (LVEF ≤40%), type 2 diabetes, and chronic kidney disease when they have persistent albuminuria (ACR ≥30 mg/g) despite maximum tolerated RAS inhibition, with eGFR ≥25 mL/min/1.73 m² and potassium ≤4.8 mmol/L.

Evidence Base and Positioning

The 2022 ADA/KDIGO consensus guidelines provide the most authoritative framework for finerenone use 1. While finerenone was primarily studied in patients with diabetic kidney disease, the cardiovascular benefits—particularly reduction in heart failure hospitalizations—extend to those with HFrEF. The 2024 ADA Standards of Care reinforce that finerenone is recommended in people with type 2 diabetes and diabetic kidney disease to reduce the risk of progression from stage A heart failure to symptomatic incident heart failure 2.

The FIDELIO-DKD and FIGARO-DKD trials demonstrated that finerenone reduced heart failure hospitalizations by 29% (HR 0.71) and cardiovascular death/nonfatal events by 13-14% 2, 3. The pooled FIDELITY analysis of 13,171 patients confirmed a 14% reduction in composite cardiovascular outcomes and 23% reduction in kidney disease progression 4, 3.

Specific Initiation Criteria

Your patient meets all criteria if they have:

• HFrEF with LVEF ≤40%
• Type 2 diabetes mellitus
• CKD with eGFR ≥25 mL/min/1.73 m²
• Serum potassium ≤4.8 mmol/L (or ≤5.0 mmol/L per FDA label)
• Persistent albuminuria (ACR ≥30 mg/g) despite maximum tolerated RAS inhibitor therapy 1

Critical caveat: Patients with heart failure with reduced ejection fraction and uncontrolled hypertension were excluded from the pivotal trials 3. Ensure blood pressure is adequately controlled before initiation.

Dosing Algorithm

Initial dose determination 1, 4:

• eGFR >60 mL/min/1.73 m²: Start 20 mg once daily
• eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily

Dose titration after 4 weeks:

• If potassium <4.8 mmol/L and eGFR stable: Uptitrate 10 mg to 20 mg daily
• If potassium ≤5.5 mmol/L: Continue current dose
• If potassium >5.5 mmol/L: Withhold finerenone; restart at 10 mg daily when potassium ≤5.0 mmol/L

Ongoing monitoring:

• Check potassium and eGFR 4 weeks after each dose change
• Continue regular monitoring during treatment
• Finerenone can be continued even if eGFR falls <25 mL/min/1.73 m² as long as potassium remains acceptable 1

Integration with Guideline-Directed Medical Therapy

Finerenone should be added to, not substituted for, foundational HFrEF therapies. The 2025 BMJ guideline emphasizes that for adults at higher risk with established cardiovascular disease or CKD, SGLT2 inhibitors or GLP-1 receptor agonists receive a strong recommendation, while finerenone receives a weak recommendation specifically for those with CKD 5.

Layering sequence:

1. First priority: SGLT2 inhibitors (strong evidence for HFrEF mortality benefit)
2. Second priority: ACE inhibitor/ARB, beta-blocker, MRA (traditional HFrEF pillars)
3. Third priority: Finerenone as additional therapy when albuminuria persists despite RAS inhibition 1

The 2024 ADA guidelines note that only 4.5% of patients in FIDELIO-DKD were on SGLT2 inhibitors 3, so the combination effects are not fully characterized. However, preclinical data suggest additive benefits 1.

Key Safety Considerations

Hyperkalemia risk: In FIGARO-DKD, hyperkalemia occurred in 10.8% of finerenone patients vs 5.3% placebo, but only 1.2% discontinued due to hyperkalemia 3. This is substantially lower than with steroidal MRAs.

Avoid dual RAS blockade: Do not combine ACE inhibitors with ARBs, as this increases hyperkalemia and acute kidney injury without added benefit 1.

Drug interactions: Finerenone is metabolized by CYP3A4. Avoid strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) and use caution with moderate inhibitors.

Clinical Context

The evidence for finerenone in HFrEF specifically comes from cardiovascular secondary outcomes in diabetic kidney disease trials, not from primary HFrEF trials. The FINEARTS-HF trial studied HFpEF/HFmrEF (LVEF ≥40%), not HFrEF 6, 7, 8. Therefore, the primary indication remains diabetic CKD with albuminuria, where heart failure hospitalization reduction is a proven benefit 2.

Bottom line: In your specific patient with HFrEF, T2DM, CKD, and albuminuria despite RAS inhibition, finerenone is reasonable to add for cardiorenal protection, but ensure SGLT2 inhibitors are prioritized first given their stronger mortality benefit in HFrEF.